Etonogestrel 68MG 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTLB
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $31,011
Award facts
- Contract value 100% obligated
- $31,010.81 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $31,010.81 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Etonogestrel 68mg contraceptive implants. The delivery order was issued on January 12, 2026, with an ultimate completion date of January 29, 2026, and carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to support Department of Defense pharmaceutical supply requirements globally.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical pharmaceutical supplier within the federal military medical system, with delivery orders spanning oncology treatments, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The company's established track record of contract performance across diverse therapeutic categories and product lines, combined with its small business status, positions it as a reliable supplier for the DLA's recurring medical supply needs. The PPV-G GEN V contract, which carries a $500 million ceiling value and extends through December 31, 2036, enables the Defense Logistics Agency to leverage DMS Pharmaceutical Group's comprehensive pharmaceutical portfolio to support military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FBTLB?
SPE2DR26FBTLB was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FBTLB worth?
The government has obligated $31,011 on SPE2DR26FBTLB.
Is contract SPE2DR26FBTLB an order under another contract?
Yes. SPE2DR26FBTLB is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTLB competed?
The extent of competition for SPE2DR26FBTLB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award